Does Kawasaki Disease Cause Pneumonitis?
Kawasaki disease can cause pulmonary manifestations including pneumonitis, though this is rare and occurs in only about 1-2% of cases. When present, pulmonary involvement typically manifests as parenchymal consolidation, peribronchial cuffing, increased interstitial markings, pulmonary nodules, or pleural effusions 1, 2.
Understanding Pulmonary Involvement in Kawasaki Disease
Documented Pulmonary Manifestations
The American Heart Association guidelines explicitly recognize pulmonary involvement as a rare but established finding in Kawasaki disease 2. Chest radiography abnormalities are observed in approximately 15% of patients, though clinically significant pneumonitis is much less common 1.
Specific pulmonary findings include:
- Peribronchial cuffing and increased interstitial markings (most common radiographic finding)
- Pulmonary nodules
- Pleural effusions
- Parenchymal consolidation
- Rarely, pneumothorax 2
Clinical Significance and Diagnostic Challenges
The key clinical challenge is that pulmonary presentations can obscure the diagnosis of Kawasaki disease, leading to delayed treatment and increased risk of coronary artery aneurysms. Recent case series demonstrate that children presenting predominantly with pulmonary symptoms (cough, respiratory distress, pneumonia) had their KD diagnosis delayed by an average of 14.5-22.4 days from fever onset 3.
Critical diagnostic clues when pneumonia is present:
- Persistent fever despite appropriate antibiotics
- Thrombocytosis (platelet count often >450,000/mm³)
- Markedly elevated inflammatory markers (ESR often >100 mm/hr, CRP >3 mg/dL)
- Progressive symptoms rather than improvement with antimicrobial therapy 4, 5, 3
Pathophysiologic Mechanism
The pulmonary involvement in Kawasaki disease represents part of the systemic vasculitis affecting medium-sized arteries throughout the body 2. The inflammatory cascade involves endothelial cell activation, CD68 monocyte/macrophages, and cytokine storm (particularly IL-6, TNF-α) that can affect pulmonary vasculature and parenchyma 2, 6.
Clinical Approach When Pneumonia and Fever Coexist
If a child presents with pneumonia that fails to respond to antibiotics after 5-7 days with persistent high fever, actively evaluate for Kawasaki disease by:
Examining for classic KD features (even if incomplete):
- Conjunctival injection (bilateral, non-exudative)
- Oral changes (cracked lips, strawberry tongue, diffuse erythema)
- Polymorphous rash
- Extremity changes (erythema, edema, or later desquamation)
- Cervical lymphadenopathy (≥1.5 cm)
Obtaining inflammatory markers:
- ESR and CRP (both typically markedly elevated in KD)
- Complete blood count (looking for thrombocytosis, anemia)
- Albumin (often low in KD)
- Liver enzymes
Performing echocardiography to assess for coronary artery abnormalities, which can establish the diagnosis even with incomplete clinical criteria 1
Important Caveats
Do not dismiss Kawasaki disease simply because pneumonia is present. The pulmonary findings may be the initial or predominant manifestation, particularly in younger infants where incomplete KD is more common 6, 3, 7.
Neonates and young infants (<6 months) are at highest risk for:
- Atypical presentations including severe pneumonia
- Delayed diagnosis
- Higher rates of coronary artery aneurysms if untreated 6
The presence of co-infections (including Mycoplasma pneumoniae, Influenza A, Group A Streptococcus, or Human Metapneumovirus) does not exclude Kawasaki disease and may actually trigger KD in genetically susceptible individuals 4, 8, 9.
Treatment Implications
Once Kawasaki disease is diagnosed, even in the presence of pneumonia, standard KD treatment should be initiated promptly:
- IVIG 2 g/kg as single infusion
- High-dose aspirin (80-100 mg/kg/day divided into four doses)
- Treatment should ideally occur within 10 days of fever onset but should still be given if fever or inflammation persists beyond 10 days 1
Recent case reports demonstrate that pulmonary manifestations, including severe pneumonia requiring mechanical ventilation, resolve following appropriate IVIG therapy for Kawasaki disease 4, 6.